**
A recent survey reveals that approximately three million adults in Canada are currently using GLP-1 medications, such as Ozempic and Mounjaro, primarily for weight loss and diabetes management. The study, conducted by Leger Healthcare, indicates that while many Canadians are keen on these treatments, the high costs and insurance limitations pose significant barriers to access. This shift in medication use is not merely a health trend; it is transforming consumer behaviour and dietary choices across the nation.
Changing Consumer Habits
The findings of the survey, which involved 1,536 Canadians aged 18 and older from February 6 to 9, 2026, illustrate how the introduction of GLP-1 drugs is influencing everyday life. Over half of the participants reported experiencing a reduced appetite, with 40% noting fewer food cravings. This has led to noticeable changes in spending habits; around 30% of users are dining out less frequently and opting for healthier food options. A significant portion of respondents, approximately one-third, have increased their purchases of fresh fruits, vegetables, and protein-rich foods.
“GLP-1s are no longer a niche health topic. They’re a mainstream consumer and healthcare story,” remarked Melicent Lavers-Sailly, vice-president of research at Leger Healthcare. The implications of these medications extend beyond prescriptions, reshaping shopping behaviours and lifestyle choices.
Health Considerations and Barriers to Access
While the allure of GLP-1 medications is clear, the survey highlights substantial barriers faced by potential users. Around half of those interested in trying these drugs cited cost and lack of insurance coverage as significant obstacles. Furthermore, 36% expressed a willingness to consider GLP-1s if the risk of side effects were lower. Common gastrointestinal side effects, including nausea and vomiting, can deter individuals from committing to treatment.
The survey revealed that 58% of participants taking or contemplating GLP-1 medications identified weight loss as their primary motivation, while 42% pointed to diabetes management. Interestingly, 22% of respondents were motivated by concerns about heart health, with men more likely to express this reason than women.
Financial Implications of GLP-1 Use
The financial burden of GLP-1 medications is substantial, with around a quarter of users paying out of pocket for treatments that can amount to hundreds of dollars monthly. Approximately 28% of respondents reported that their medications were fully covered by private or public insurance, while nearly half indicated having partial coverage. This financial landscape underscores the need for policy discussions around accessibility and affordability of essential medications in Canada.
Leger Healthcare estimates that around two million Canadian adults are interested in GLP-1 treatments but are currently unable to access them. This gap highlights not only an urgent health concern but also a broader societal issue regarding equitable healthcare access.
Evolving Perspectives on Health and Wellness
As GLP-1 medications gain popularity, they spark conversations within the body positivity movement and the broader discourse on health and wellness. The impact of these drugs raises questions about societal attitudes towards weight, health, and self-image. The potential benefits of weight loss must be weighed against the risks of reinforcing harmful beauty standards and the complexities of individual health journeys.
Why it Matters
The rising use of GLP-1 medications marks a significant shift in how Canadians approach health and wellness, intertwining medical treatment with lifestyle choices and consumer behaviour. Understanding this trend is crucial, as it underscores the importance of affordable healthcare access while illuminating the complex relationship between medication, societal expectations, and individual well-being. As the landscape of health continues to evolve, it is imperative that discussions around these medications remain inclusive, addressing both the benefits and the challenges they present.